CN103703174B - 联合药物组合物及其用途 - Google Patents

联合药物组合物及其用途 Download PDF

Info

Publication number
CN103703174B
CN103703174B CN201280033418.1A CN201280033418A CN103703174B CN 103703174 B CN103703174 B CN 103703174B CN 201280033418 A CN201280033418 A CN 201280033418A CN 103703174 B CN103703174 B CN 103703174B
Authority
CN
China
Prior art keywords
alkyl
aryl
heteroaryl
alkynyl
alkenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280033418.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN103703174A (zh
Inventor
刘异
任平达
卡塔洋·杰森
鑫·郭
C·罗梅尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Intellikine LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intellikine LLC filed Critical Intellikine LLC
Publication of CN103703174A publication Critical patent/CN103703174A/zh
Application granted granted Critical
Publication of CN103703174B publication Critical patent/CN103703174B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201280033418.1A 2011-05-04 2012-05-04 联合药物组合物及其用途 Active CN103703174B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161482568P 2011-05-04 2011-05-04
US61/482,568 2011-05-04
PCT/US2012/036688 WO2012151562A1 (en) 2011-05-04 2012-05-04 Combination pharmaceutical compositions and uses thereof

Publications (2)

Publication Number Publication Date
CN103703174A CN103703174A (zh) 2014-04-02
CN103703174B true CN103703174B (zh) 2017-05-10

Family

ID=47108075

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280033418.1A Active CN103703174B (zh) 2011-05-04 2012-05-04 联合药物组合物及其用途

Country Status (7)

Country Link
US (2) US20140357651A1 (OSRAM)
EP (1) EP2705181B1 (OSRAM)
JP (1) JP6047149B2 (OSRAM)
CN (1) CN103703174B (OSRAM)
CA (1) CA2836769C (OSRAM)
ES (1) ES2618489T3 (OSRAM)
WO (1) WO2012151562A1 (OSRAM)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006068760A2 (en) 2004-11-19 2006-06-29 The Regents Of The University Of California Anti-inflammatory pyrazolopyrimidines
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
EP2705181B1 (en) 2011-05-04 2016-12-21 Intellikine, LLC Combination pharmaceutical compositions and uses thereof
CN103796655A (zh) * 2011-05-06 2014-05-14 加利福尼亚大学董事会 多囊性疾病的治疗
CA2907726A1 (en) * 2013-03-22 2014-09-25 Millennium Pharmaceuticals, Inc. Combination of catalytic mtorc1/2 inhibitors and selective inhibitors of aurora a kinase
US20160367627A1 (en) 2013-07-02 2016-12-22 Nikolai Khodarev Anti-tumor therapy
JP6725501B2 (ja) 2014-07-02 2020-07-22 ザビエル・ユニバーシティ・オブ・ルイジアナＸａｖｉｅｒ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｌｏｕｉｓｉａｎａ 少なくとも１つのフェノール（または芳香族ヒドロキシル）基を含有する薬物分子に関する増大された生物学的利用能及びより低い必要用量のためのホウ素系プロドラッグ戦略
WO2016040806A1 (en) 2014-09-11 2016-03-17 The Regents Of The University Of California mTORC1 INHIBITORS
US10118890B2 (en) 2014-10-10 2018-11-06 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
US10214537B2 (en) 2014-10-22 2019-02-26 Bristol-Myers Squibb Company Bicyclic heteroaryl amine compounds
US10023576B2 (en) 2014-10-22 2018-07-17 Bristol-Myers Squibb Company Heteroaryl substituted pyrrolotriazine amine compounds as PI3K inhibitors
US10532226B2 (en) * 2014-12-24 2020-01-14 The University Of North Carolina At Chapel Hill Combined local delivery of therapeutic agents using interventional devices and radiation
TWI753892B (zh) 2016-03-28 2022-02-01 美商英塞特公司 作為ｔａｍ抑制劑之吡咯并三嗪化合物
CN115650985B (zh) 2016-04-15 2024-08-02 癌症研究科技有限公司 作为ret激酶抑制剂的杂环化合物
WO2017178845A1 (en) 2016-04-15 2017-10-19 Cancer Research Technology Limited Heterocyclic compounds as ret kinase inhibitors
CA3039582A1 (en) * 2016-10-07 2018-04-12 Abraxis Bioscience, Llc Methods of treating biliary tract cancer
GB201705971D0 (en) 2017-04-13 2017-05-31 Cancer Res Tech Ltd Inhibitor compounds
FR3075795A1 (fr) * 2017-12-21 2019-06-28 Galderma Research & Development Nouveaux composes inhibiteurs de mtor
FR3075794A1 (fr) 2017-12-21 2019-06-28 Galderma Research & Development Nouveaux composes inhibiteurs de mtor
FI3788049T3 (fi) 2018-05-01 2023-05-30 Revolution Medicines Inc C40-, c28- ja c-32-liittyneitä rapamysiinianalogeja mtor-estäjinä
MX2020011564A (es) 2018-05-01 2021-01-29 Revolution Medicines Inc Analogos de rapamicina unidos a c26 como inhibidores de mtor.
WO2021157689A1 (ja) * 2020-02-07 2021-08-12 範行 東 細胞周期のｇ１期初期制御剤
US12014835B2 (en) 2020-02-19 2024-06-18 Vanderbilt University Methods for evaluating therapeutic benefit of combination therapies
WO2021168283A1 (en) * 2020-02-19 2021-08-26 Vanderbilt University Therapeutic methods and compositions for treating cancer using braf and/or mek inhibitor combination therapy
TW202402277A (zh) 2022-05-25 2024-01-16 美商銳新醫藥公司 以mtor抑制劑治療癌症之方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6709676B2 (en) * 1999-12-20 2004-03-23 Schering Corporation Extended release oral dosage composition
WO2009008992A2 (en) * 2007-07-06 2009-01-15 Osi Pharmaceuticals Inc. Combination anti-cancer therapy comprising an inhibitor of both mtorc1 and mt0rc2
US20100184760A1 (en) * 2008-11-03 2010-07-22 Pingda Ren Benzoxazole kinase inhibitors and methods of use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009114874A2 (en) * 2008-03-14 2009-09-17 Intellikine, Inc. Benzothiazole kinase inhibitors and methods of use
US9096611B2 (en) 2008-07-08 2015-08-04 Intellikine Llc Kinase inhibitors and methods of use
WO2010036380A1 (en) 2008-09-26 2010-04-01 Intellikine, Inc. Heterocyclic kinase inhibitors
US20110195966A1 (en) * 2008-10-31 2011-08-11 Novartis Ag Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor
EP2705181B1 (en) 2011-05-04 2016-12-21 Intellikine, LLC Combination pharmaceutical compositions and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6709676B2 (en) * 1999-12-20 2004-03-23 Schering Corporation Extended release oral dosage composition
WO2009008992A2 (en) * 2007-07-06 2009-01-15 Osi Pharmaceuticals Inc. Combination anti-cancer therapy comprising an inhibitor of both mtorc1 and mt0rc2
US20100184760A1 (en) * 2008-11-03 2010-07-22 Pingda Ren Benzoxazole kinase inhibitors and methods of use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Aissat et al..Antiproliferative eVects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines.《Cancer Chemother Pharmacol》.2008, *
Antiproliferative eVects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines;Aissat et al.;《Cancer Chemother Pharmacol》;20081231;307页左栏第2段，309左栏第3段至310页右栏第2段，图6 *
Concurrent and Sequential Administration of Chemotherapy and the Mammalian Target of Rapamycin Inhibitor Temsirolimus in Human Cancer Cells and Xenografts;Andrea S. Fung et al.;《Clin Cancer Res》;20090825;5389-5395 *

Also Published As

Publication number Publication date
EP2705181A1 (en) 2014-03-12
CA2836769A1 (en) 2012-11-08
JP6047149B2 (ja) 2016-12-21
CN103703174A (zh) 2014-04-02
US20160287595A1 (en) 2016-10-06
JP2014513138A (ja) 2014-05-29
US20140357651A1 (en) 2014-12-04
EP2705181B1 (en) 2016-12-21
WO2012151562A1 (en) 2012-11-08
CA2836769C (en) 2018-11-13
US10172858B2 (en) 2019-01-08
HK1195793A1 (en) 2014-11-21
EP2705181A4 (en) 2014-10-08
ES2618489T3 (es) 2017-06-21

Similar Documents

Publication Publication Date Title
CN103703174B (zh) 联合药物组合物及其用途
CN103491962B (zh) 激酶抑制剂的组合及其用途
JP6114296B2 (ja) 複数の医薬品を使用した治療レジメン
JP6126615B2 (ja) キナーゼ阻害剤の組み合わせおよびそれらの使用
JP2016512835A (ja) キナーゼ阻害剤の組み合わせ及びそれらの使用
CN104363914A (zh) 使用mTOR抑制剂的增强的治疗方案
WO2012154608A1 (en) Reactive mtor and pi3 kinase inhibitors and uses thereof
HK1236441A1 (zh) 激酶抑制劑的組合及其用途
HK1236441A (en) Combination of kinase inhibitors and uses thereof
HK1195793B (en) Combination pharmaceutical compositions and uses thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20211104

Address after: Osaka, Japan

Patentee after: TAKEDA PHARMACEUTICAL Co.,Ltd.

Address before: California, USA

Patentee before: INTELLIKINE, LLC

TR01 Transfer of patent right